Ignite Creation Date:
2024-05-05 @ 11:42 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00113256
Status:
TERMINATED
Last Update Posted:
2013-01-23
First Post:
2005-06-06
Brief Title:
Orathecin Gemcitabine Versus Placebo Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer
Sponsor:
Astex Pharmaceuticals Inc
Organization:
Astex Pharmaceuticals Inc
Study Overview
Official Title:
Randomized Trial of Orathecin and Gemcitabine Versus Placebo and Gemcitabine in Patients With Non-Resectable Pancreatic Cancer Who Have Not Already Received Chemotherapy
Status:
TERMINATED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients will be treated with gemcitabine and Orathecin rubitecan capsules to evaluate the current estimate of overall survival as a study endpoint prior to launching the blinded randomized phase versus gemcitabine and placebo of the study Toxicity of the drug combination will also be evaluated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None